ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Catalase Inhibitors with Dual Pro-Oxidant Effect as New Therapeutic Agents in Castration-Resistant Prostate Cancer

Chen, Yuan-Yuan; Liang, Hao-Qi; Liu, Meng-Ting; Huang, Wei; Yi, Peng-Fei; Yuan, Si-Qi; Mei, Long-Can; Hu, Ying-Hui; Cao, Ya-Ya; Hao, Ge-Fei; Zhang, Dan*; Yang, Guang-Fu*华中科技大学
ADVANCED THERAPEUTICS2021-3DOI: 10.1002/adtp.202000164
1被引6阅读
引用收藏
分享

摘要

Almost all patients with advanced prostate cancer (PCa) will eventually progress to incurable castration-resistant PCa (CRPC) if endocrine therapy fails. Therefore, identifying potential cellular targets is critical for the development of novel and effective treatments for CRPC. Based on the investigation of the molecular mechanism of ATN-224, an anticancer drug in clinical trials, in CRPC DU145 cells, the antioxidant enzyme catalase (CAT) has been recognized as an actionable CRPC therapeutic target, and the modulation of intracellular redox state through CAT inhibition has great potential for CRPC treatment. After systematic design and synthesis, the benzaldehyde thiosemicarbazone derivative BT-1 is shown to be effective CAT inhibitor in DU145 cells. This inhibition induces the significant increase of both superoxides (O-2(center dot-)) and H2O2 levels in DU145 cells. Finally, the dual pro-oxidant effect of BT-1 is demonstrated to lead to apoptosis as well as cell-cycle arrest in DU145 cells, effectively reducing CRPC tumors.

学科与关键词

关键词
castration-resistant prostate cancercatalase inhibitorsdual pro-oxidant effects
相关
加载中…
  • A catalase inhibitor: Targeting the NADPH-binding site for castration-resistant prostate cancer therapy
    Cao, Ya Ya; Chen, Yuan Yuan; Wang, Ming Shu; Tong, Jing Jing; Xu, Meng; Zhao, Chi; Lin, Hong Yan; Mei, Long Can; Dong, Jin; Zhang, Wen Lin; Qin, Yu Xuan; Huang, Wei; Zhang, Dan*; Yang, Guang Fu*Redox Biology, 2023, 63: 102751.被引 3
  • Regression of Castration-Resistant Prostate Cancer by a Novel Compound HG122
    Cong, Xiaonan; He, Yundong; Wu, Haigang; Wang, Dingxiang; Liu, Yongrui; Shao, Ting; Liu, Mingyao; Yi, Zhengfang; Zheng, Jianghua; Peng, Shihong*; Ding, Tao*Frontiers in Oncology, 2021, 11: 650919.被引 4
  • Abiraterone acetate: A novel drug for castration-resistant prostate carcinoma
    R, NandhaJournal of Postgraduate Medicine, 2012, 58(3): 203.
查看全部 →

发表信息

论文状态
公开发表
期刊
ADVANCED THERAPEUTICS
发表日期
2021-03
卷期
第 4 卷, 第 3 期
页码
2000164
DOI
10.1002/adtp.202000164
成果收录
SCIE
资助标注
National Key Research and Development Program of China [2017YFA0505203]; National Natural Science Foundation of China [21877045]; 111 Program [B17019]; Chemical Biology Center, College of Chemistry, Central China Normal University

作者

  • C

    Chen, Yuan-Yuan (第一作者)

    cent china normal univ

  • L

    Liang, Hao-Qi

    cent china normal univ

查看全部 12 位作者收起作者
  • L

    Liu, Meng-Ting

    cent china normal univ

  • H

    Huang, Wei

    cent china normal univ

  • Y

    Yi, Peng-Fei

    huazhong univ sci & technol

  • Y

    Yuan, Si-Qi

    cent china normal univ

  • M

    Mei, Long-Can

    cent china normal univ

  • H

    Hu, Ying-Hui

    cent china normal univ

  • C

    Cao, Ya-Ya

    cent china normal univ

  • H

    Hao, Ge-Fei

    cent china normal univ

  • Z

    Zhang, Dan (通讯)

    cent china normal univ

  • Y

    Yang, Guang-Fu (通讯)

    cent china normal univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417